Search

Displaying results 6001 - 6010 of 6189 in total
  1. Drug

    Semaxanib

    go.drugbank.com/drugs/DB06436
    Investigational

  2. Drug

    Posizolid

    go.drugbank.com/drugs/DB04850
    Investigational

    Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial...

  3. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.

  4. Drug

    Pelitinib

    go.drugbank.com/drugs/DB05524
    Investigational

    Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.

  5. Drug

    TRU-015

    go.drugbank.com/drugs/DB05580
    Investigational

  6. Drug

    CRD5

    go.drugbank.com/drugs/DB05587
    Experimental

  7. Drug

    Custirsen

    go.drugbank.com/drugs/DB05487
    Investigational

    Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. … This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms.

  8. Drug

    IPH 1101

    go.drugbank.com/drugs/DB05754
    Experimental

    IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform

  9. Drug

    Diethylnorspermine

    go.drugbank.com/drugs/DB06445
    Investigational

  10. Drug

    MKC-1

    go.drugbank.com/drugs/DB05608
    Investigational